Global Liquid Biopsy & Other Non-Invasive Cancer Diagnostics Market, 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers

News provided by

Dec 19, 2019, 08:30 ET

DUBLIN, Dec. 19, 2019 /PRNewswire/ -- The "Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers" report has been added to ResearchAndMarkets.com's offering.

This report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across:

[A] type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others)
[B] key applications (early diagnosis, patient monitoring and recurrence monitoring)
[C] target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others)
[D] end users (hospitals, research institutes and others)
[E] key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and rest of the world)

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Advances in the field of biotechnology have enabled the establishment of several minimally invasive / non-invasive approaches for disease diagnosis

Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool. This procedure is based on the analysis of biofluids (such as blood, urine and / or plasma) in order to detect rare forms of biomarkers / tumor markers, such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs), circulating free DNA (cfDNA) and exosomes. Moreover, liquid biopsies have been demonstrated to be capable of assessing the stage of tumor at the time of sample extraction. Additionally, owing to the non-invasive nature of the test, it can be actively used to monitor / track changes in tumors, both before and during the course of treatment.

Other than liquid biopsy, the cancer diagnostics market has witnessed the emergence of several other non-invasive diagnostic technologies, which are based on analytes that are either superficially located (such as skin lesions) and / or are expelled from the body (such as bronchial fluids and exhaled breath). Most of the non-invasive diagnostic techniques mentioned above are backed by clinical data, validating their relevance and applicability across several types of solid tumors (such as breast cancer, lung cancer, ovarian cancer and pancreatic cancer) and hematological malignancies (such as leukemia and lymphoma). In future, non-invasive cancer diagnosis methods, particularly liquid biopsies, are anticipated to replace the existing invasive diagnostic techniques.

Amongst other elements, the report includes:

A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.
An analysis of the initiatives of big pharma players, highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.
A detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.
Elaborate profiles of the key players engaged in this domain, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, recent developments and an informed future outlook.

Key Topics Covered

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer-related Statistics and Current Disease Burden
3.3. Importance of Early Cancer Detection
3.4. Cancer Screening and Diagnosis
3.5. Conventional Methods of Cancer Diagnosis
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Cancer Diagnostics
3.7. Liquid Biopsy and Other Non-Invasive Cancer Diagnostics
3.7.1. Liquid Biopsy
3.7.1.1. Relevance and Analysis of Circulating Tumor Cells
3.7.1.2. Relevance and Analysis of Circulating Tumor DNA
3.7.1.3. Relevance and Analysis of Exosomes
3.7.2. Other Non-Invasive Cancer Diagnostics
3.7.3. Benefits of Non-Invasive Cancer Diagnostics
3.7.4. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.7.5. Challenges Associated with Non-Invasive Cancer Diagnostics
3.8. Future Perspectives

4. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-ray Radiography (Barium Enema)
4.3. Screening Assays
4.3.1. Circulating Tumor Marker Test
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Test (FOBT)
4.3.4. Multigated Acquisition (MUGA) Scan
4.3.5. Human Papilloma Virus Test and Papanicolaou Test
4.4. Advanced Non-Invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Molecular Signature-based Non-Invasive Methods
4.4.3. Saliva-based Oral Cancer Diagnostics
4.4.4. Vital Staining
4.4.5. Optical Biopsy
4.4.6. Other Diagnostic Techniques

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy Products: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size and Geographical Location
5.2.3. Leading Players: Analysis by Number of Products
5.3. Liquid Biopsy Products: List of Available / Under Development Products
5.3.1. Analysis by Application Area
5.3.2. Analysis by Target Cancer Indication
5.3.3. Analysis by Type of Tumor Marker
5.3.4. Analysis by Type of Analyte
5.3.5. Analysis by Status of Development
5.4. Liquid Biopsy Products: Affiliated Technology Platforms, Systems and Instruments
5.5. Liquid Biopsy Products: List of Contract Service Providers

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Amoy Diagnostics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Liquid Biopsy Product Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. DiaCarta
6.4. HaploX
6.5. NeoGenomics
6.6. QIAGEN
6.7. Swift Biosciences
6.8. Sysmex Inostics
6.9. Thermo Fisher Scientific

7. NON-INVASIVE CANCER DIAGNOSTICS-RELATED INITIATIVES OF BIG PHARMA PLAYERS
7.1. Chapter Overview
7.2. Top Pharmaceutical Companies
7.2.1. Analysis by Application Area
7.2.2. Analysis by Target Cancer Indication
7.2.3. Analysis by Type of Tumor Marker
7.2.4. Analysis by Status of Development of Product

8. KEY ACQUISITION TARGETS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Potential Strategic Acquisition Targets: Analysis by Geography
8.3.1. Potential Strategic Acquisition Targets in North America
8.3.1.1. Scoring Criteria
8.3.1.2. Likely Targets
8.3.2. Potential Strategic Acquisition Targets in Europe
8.4. Potential Strategic Acquisition Targets: Analysis by Product Portfolio

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Tumor Marker
9.3.4. Analysis by Target Cancer Indication
9.3.5. Analysis by Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.7.1. Intercontinental and Intracontinental Partnerships

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. List of Funding and Investment Instances
10.3.1. Analysis by Number of Funding Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Target Cancer Indication
10.3.5. Analysis by Tumor Marker
10.3.6. Most Active Players: Analysis by Amount Invested
10.3.7. Most Active Investors: Analysis by Number of Funding Instances
10.3.8. Regional Analysis by Amount Invested
10.4. Concluding Remarks

11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood-based Biomarker Detection Tests
11.3. DNA Methylation-based Tests
11.4. FOBT and Fecal Immunochemical Tests (FIT)
11.5. MicroRNA (miRNA)-based Tests
11.6. Pigmented Lesion Assays
11.7. Stool DNA (sDNA)-based Tests
11.8. Volatile Organic Compound (VOC) Detection Tests
11.9. Other Non-Invasive Cancer Diagnostics

12. SURVEY ANALYSIS
12.1. Chapter Overview
12.2. Other Non-Invasive Cancer Diagnostics: Survey Analysis
12.2.1. Overview of Respondents
12.2.2. Designation of Respondents
12.2.3. Product Portfolio
12.2.4. Type of Product / Service Offered
12.2.5. Application Area
12.2.6. Status of Development of Product
12.2.7. Likely Market Size

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030
13.3.1. Global Liquid Biopsy Market, 2019-2030
13.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030
13.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030
13.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030
13.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030
13.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030
13.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030
13.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030
13.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030
13.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030
13.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030
13.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030
13.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030
13.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030
13.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030
13.3.1.2.10. Global Liquid Biopsy Market for Other Cancers, 2019-2030
13.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030
13.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030
13.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030
13.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030
13.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030
13.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030
13.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030
13.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030
13.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
13.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030
13.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030
13.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030
13.3.1.5.3. Global Liquid Biopsy Market for Other End User, 2019-2030
13.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030
13.3.1.6.1 Liquid Biopsy Market in the US, 2019-2030
13.3.1.6.2 Liquid Biopsy Market in the UK, 2019-2030
13.3.1.6.3 Liquid Biopsy Market in Germany, 2019-2030
13.3.1.6.4 Liquid Biopsy Market in Italy, 2019-2030
13.3.1.6.5 Liquid Biopsy Market in Spain, 2019-2030
13.3.1.6.6 Liquid Biopsy Market in France, 2019-2030
13.3.1.6.7 Liquid Biopsy Market in Japan, 2019-2030
13.3.1.6.8 Liquid Biopsy Market in Australia, 2019-2030
13.3.1.6.9 Liquid Biopsy Market in China, 2019-2030
13.3.1.6.10 Liquid Biopsy Market in India, 2019-2030
13.3.1.6.11 Liquid Biopsy Market in Rest of the World, 2019-2030
13.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030

14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Genostics
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Joachim Fluhrer, Founder and Medical Director
15.3. Theranosis Life Sciences
15.4. Proxeom
15.5. MiNDERA
15.6. IVDiagnostics
15.7. Resolution Bioscience
15.8. Minomic International
15.9. Nanostics
15.10. Tymora Analytical Operations
15.11. DermTech
15.12. iCellate Medical
15.13. VolitionRx
15.14. OncoDNA
15.15. LCM Genect
15.16. Sienna Cancer Diagnostics

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

360 Capital Partners
4D Lifetec
50K Ventures
5AM Ventures
6 Dimensions Capital
A&G Pharmaceutical
Abbott
Abcodia
Accu Reference Medical Lab
AccuraGen
Ackermans & van Haaren
Acobiom
Acousys Biodevices
Active Motif
Acuamark Diagnostics
ADC Therapeutics
Addario Lung Cancer Medical Institute
Admera Health
Advanced Wave Sensors
Affymetrix
AGCT
Agena Bioscience
Agilent Technologies
Agiomix
Ahren Innovation Capital
Alabama Capital Network
Albert & Annas Minne Foundation
Alentia Capital Alternativo
Alexandria Venture Investments
Alliance Global
Ally Bridge Group
Alychlo
Amadix
AMAL Therapeutics
Amazon
Amedes Group
Amer International Group
America's Choice Provider Network
American Bio Services
Amgen
Amoy Diagnostics
Anchor Molecular
ANCON Medical
Andreessen Horowitz
ANGLE
Anixa Biosciences
Annoroad Gene Technology
Anpac Bio
Anthill Ventures
Apostle
Arboretum Ventures
ARCH Venture Partners
ArcherDX
ARNA Genomics
Arquer Diagnostics
ArrayGenomics
Arrow Diagnostics
Artiman Ventures
ARUP Laboratories
ASB Ventures
Asia Genomics
ASPiRA LABS
AstraZeneca
Astrimmune
Asuragen
Aurum Ventures
AVIVA Biosciences
Balderton Capital
Bangkok Molecular Genetics
BARD1 Life Sciences
BeAble Capital
BeaconLBS
Bellwether Bio
Best Med Opinion
Beth Israel Deaconess Medical Center
Betta Pharmaceuticals
Bezos Expeditions
BGI Genomics
Bill & Melinda Gates Foundation
Biocartis
Biocept
BioChain
Biodesix
BioDiscovery
Bioeconomy Capital
BioFluidica
BIOHAL
BioHisto Maroc
Biolidics
Biological Dynamics
BioMarCare Technologies
BioMark Diagnostics
BiomaRx
BIOPROGNOS
Bio-Rad Laboratories
Biosearch Technologies
BioSequence
BioVeda China Fund (BVCF)
BioVendor
BioView
Bioyong Technology
BloodPAC
Blue Pool Capital
Bluestar Genomics
BNO BIO
Boehringer Ingelheim
Boreal Genomics
Boston Children's Hospital
Breath Diagnostics
BrightEdge Ventures
Bristol-Myers Squibb
BSN
Burning Rock Biotech
Cambridge Epigenetix
Cambridge Innovation Capital
Cambridge University
CANCER-ID
Canostix
Capio Biosciences
Capital Research and Management
CareFirst BlueCross BlueShield
Caris Life Sciences
Cathay Fortune International
CDBI Partners
Celgene
CellMax Life
Celsee
Checkmate Pharmaceuticals
China Biotech Services
China Merchants Securities International
Chronix Biomedical
CIRCULOGENE
Cirina
Cleveland Diagnostics
Clinical Genomics
Clinomics
CloudHealth Genomics
Cloudstone Venture Fund
Co-Diagnostics
Colorectal Cancer Alliance
ConquerX
CORE Diagnostics
Cornerstone Total Return Fund
Cowin Venture Capital
CPH Capital
CryoGene
Cyclomics
Cynvenio-Livzon Diagnostics
Cytofind Diagnostics
Cytosystems
Data Collective
Datar Cancer Genetics
Decheng Capital
Delee
Denlux Capital
DermTech
DiaCarta
DiaDx
Diagnolita
Diagnostics Development Hub
DIAN Diagnostics
Diatech Pharmacogenetics
DiuVita Diagnostics
DNA Labs India
Dow Biomedica
DT Capital
Durviz
EarlyDx
EDP Biotech
EKF Diagnostics
Elypta
EONE Diagnomics Genome Center
Epic Sciences
Epigenomics
Eurobio Scientific
Eurofins Biomnis
European Association for Predictive, Preventive & Personalised Medicine
European Commission
European Organisation for Research and Treatment of Cancer
Exact Sciences
Exalt Diagnostics
ExBiome
Exosome Diagnostics
Exosomics
Expedeon
Fr Capital
Flagship Biosciences
Fluxion Biosciences
Fortune Fountain Capital
Fosun Pharmaceutical
Foundation Medicine
Fountain Medical Development
Fox Chase Cancer Center
Franklin Templeton Investments
Frederick National Laboratory for Cancer Research
Freenome
Fudan-Taizhou Institute of Health Sciences
GEM Global Yield Fund
GeneCast Biotechnology
Generation Investment Management
Geneseq Biosciences
Genetics Research
Genetracer Biotech
GENEWIZ
GENEXT
Genomenon
Genomic Health
Genomics England
Genomictree
Genoptix
Genostics
GILUPI
Glycanostics
Good Health Capital
GRAIL
Great Lakes New England Clinical Validation Center
Green Pine Capital Partners
Guangzhou Wondfo Biotech
Guardant Health
Gunnar Nilsson Cancer Foundation
GV
Hadean Ventures
HaploX
HarlePhil Ventures
HDFC
HealthCor Partners Management
HEDA Ventures
Helice Genomic Sciences
Helsinn Investment Fund
Highlight Capital
Hillhouse Capital Group
hrmed.tech
HuangPu River Capital (HPR)
Hummingbird Diagnostics
Hvidovre Hospital
Hyderabad Angels
ICBC International
iCellate Medical
Idinvest Partners
iGenetic Diagnostics
Ikonisys
Illumina
Immodulon Therapeutics
Impact Lab
Imperial Innovations
IncellDx
Indian Angel Network
Inivata
Innovative Diagnostic Laboratory
Innovatus Capital Partners
Inova Strategic Investments
Inovio Pharmaceuticals
Institut Jules Bordet
Integrated Diagnostics Holdings
International Medical Center
Interpace Diagnostics
Intezyne
Inventures
Invitek Molecular
Invoke Capital
IP Group
BIO.be
IPS Genomix
IV Diagnostics
Janssen Diagnostics
Jennison Associates
Johnson & Johnson Innovation
Jointown Pharmaceutical Group
JTS Health Partners
Junson Capital
Kaiser Permanente Ventures
KEODES
Kexin Capital
LABLAB
Laboratory for Advanced Medicine
Lariat Biosciences
Levine Cancer Institute
Lexent Bio
LifeArc
LifeX
Lilly Asia Ventures
Limitless Earth
Liquid Biotech
Lonza
Loyal Valley Capital
LU Holding
Lucence Diagnostics
LungLife AI
MagBio Genomics
Martell Biosystems
Maryland Venture Fund
Mascots Medical and Laboratory Center
Massive Genomics
Matrix Partners China
Mayo Clinic
McKesson Ventures
MDNA Life Sciences
MDxHealth
MedCDx
MedGenome
Medigen Biotechnology
MediNcrease Health Plans
MedStar Health
Menarini Silicon Biosystems
Merck
Mercy BioAnalytics
Metabolomic Technologies
Metamark
MGI Tech
MiCareo
Microgenomics
Micromedic Technologies
Milost Global
Miltenyi Biotec
Mindera
Ministry of Health Singapore
Minomic International
MIODx
miR Scientific
MiRXES
MolecularMatch
MolecularMD
MRM Proteomics
multimmune
Mumbai Angels
Mursla
Myriad Genetics
Nan Fung Group
Nanjing Kaiyuan Growth Capital Investments
Nanostics
NantHealth
Natera
National Cancer Institute
National Institutes of Health
National Taiwan University
Naveris
NEO New Oncology
NeoGeneStar
NeoGenomics
Neon Therapeutics
Netherlands Organization for Scientific Research
NeuMoDx
New Enterprise Associates
New Jersey Economic Development Authority
New Science Ventures
NIRAMAI Health Analytix
NM Genomix
Nodexus
N-of-One
Nonacus
Norgen Biotek
North Carolina Biotechnology Center
Novartis
Novigenix
nRichDX
Nucleix
NueHealth
NuGEN
NuView Life Sciences
NVIGEN
OHSU Knight Cancer Institute
oncgnostics
Oncimmune
OncoCyte
Oncode Institute
Oncode Scientific
OncoDNA
Oncolys BioPharma
Oncore Pharma
OncoSeek
OPKO Health
OrbiMed Advisors
rebro University Hospital
ORI Healthcare Fund
Owlstone Medical
Oxford Gene Technology
Pacific Edge
PANAGENE
Pangaea Oncology
Pantai Premier Pathology
Paragon Genomics
Parampara Fund
ParkwayHealth Laboratory
PathGroup
Perceptive Advisors
PeriRx
Personal Genome Diagnostics
Pfizer
Pillar Biosciences
pluriSelect Life Science
Polaris Partners
Polymedco
Polymer Char
Positive Bioscience
Precipio
Precision for Medicine
Predicine
Prescient Metabiomics
Prevail Partners
Prime Value Capital Management
Progenetics
Prognos
Prosperico Venture
Protagen Diagnostics
PROVIDENS
Provista Diagnostics
QIAGEN
Qianjiang Capital
Quantitative Cancer Diagnostix (QCDx)
Quest Diagnostics
Quidel
RA Capital Management
RainDance Technologies
Rarecells Diagnostics
RareCyte
Regionalt Cancercentrum
Reig Jofre Future Health
Resolution Bioscience
ResourcePath
RGCC Group
Roche
Rongsheng Investment
R-Pharm
RT Ventures
Sabartech
SAGA Diagnostics
Saha Fund
Sambrinvest
Sangel Capital
SanoLiBio
Sarah Cannon Research Institute
Savicell Diagnostics
Savran Technologies
SB China Venture Capital
ScreenCell
Seer
Sequoia Capital
SeraCare Life Sciences
Sevident
Shanghai Fosun Long March Medical Science
Shenzhen Innovation Investment Group
Sienna Cancer Diagnostics
Simfo
Singapore Diagnostics
Singlera Genomics
Skne University Hospital
Socit Rgionale d'Investissement de Wallonie (SRIW)
Sofina
Sofinim
Sofinnova Ventures
SOPHiA GENETICS
Speclipse
StageZero Life Sciences
STEMCELL Technologies
Strand Life Sciences
StrandSmart
Streck
Stroke Detection Plus
Sungent BioVenture
Sutter Hill Ventures
Suzhou Kintor Pharmaceuticals
Swift Biosciences
Syncona Partners
Sysmex Inostics
T Rowe Price Associates
Taiwan Government Industrial Development Bureau, Ministry of Economic
Takara Bio
TAKE2
Takeda
Tarvand Sina Tajhiz
TATAA Biocenter
Tech Transfer UPV
Telegraph Hill Partners
Temasek
Tempus
Tencent
The Heritage Group
The University of Texas MD Anderson Cancer Center
The W Fund
Theranosis Life Sciences
Thermo Fisher Scientific
THG Ventures
Thrive Earlier Detection
Todos Medical
Torna Kapital
Torpedo Diagnostics
Tranzend
TSH Biopharm
Tymora Analytical Operations
UCF Medical Investment
United States Department of Veterans Affairs
Unitus Ventures
Universal Diagnostics
University Campus Bio-Medico of Rome
University of Alabama at Birmingham
University of Minnesota
University of Texas Health Science Center
Varian Medical Systems
Velox Biosystems
Verily Life Sciences
Viatar CTC Solutions
Vienomics
Vigilant Biosciences
Vinsovier
VisionGate
VolitionRx
Vortex Biosciences
West Cancer Center
Windham Venture Partners
Wisemont Capital
WntResearch
Woodford Patient Capital Trust
WRF Capital
WS Investment
WuXi NextCODE
XboXLab
X-ZELL
Yahui Precision Medical Fund
Yale School of Medicine
Yi Fang Group
Zehou Capital
Zinexts Life Science
Zodius
Zogen Gentica Molecular

For more information about this report visit https://www.researchandmarkets.com/r/sbihg6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets